Literature DB >> 10335012

New immunosuppressive drugs and lung transplantation: last or least?

J W van den Berg1, D S Postma, G H Koëter, W van der Bij.   

Abstract

Mesh：

Substances：

Year:  1999        PMID： 10335012      PMCID： PMC1745495          DOI： 10.1136/thx.54.6.550

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  36 in total

1.  Obliterative airway disease after heterotopic tracheal xenotransplantation: pathogenesis and prevention using new immunosuppressive agents.

Authors:  H Reichenspurner; V Soni; M Nitschke; G J Berry; T R Brazelton; R Shorthouse; X Huang; B A Reitz; R E Morris
Journal:  Transplantation       Date:  1997-08-15       Impact factor: 4.939

2.  Tacrolimus as rescue therapy for bronchiolitis obliterans syndrome.

Authors:  S Kesten; C Chaparro; M Scavuzzo; C Gutierrez
Journal:  J Heart Lung Transplant       Date:  1997-09       Impact factor: 10.247

Review 3.  Obliterative bronchiolitis.

Authors:  K Kelly; M I Hertz
Journal:  Clin Chest Med       Date:  1997-06       Impact factor: 2.878

4.  Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis.

Authors:  T Goto; T Kino; H Hatanaka; M Nishiyama; M Okuhara; M Kohsaka; H Aoki; H Imanaka
Journal:  Transplant Proc       Date:  1987-10       Impact factor: 1.066

5.  Tacrolimus therapy for persistent or recurrent acute rejection after lung transplantation.

Authors:  N R Horning; J P Lynch; S R Sundaresan; G A Patterson; E P Trulock
Journal:  J Heart Lung Transplant       Date:  1998-08       Impact factor: 10.247

6.  Mycophenolate mofetil versus azathioprine immunosuppressive regimens after lung transplantation: preliminary experience.

Authors:  D J Ross; P F Waters; M Levine; M Kramer; S Ruzevich; R M Kass
Journal:  J Heart Lung Transplant       Date:  1998-08       Impact factor: 10.247

Review 7.  Sirolimus, a new, potent immunosuppressive agent.

Authors:  P A Kelly; S A Gruber; F Behbod; B D Kahan
Journal:  Pharmacotherapy       Date:  1997 Nov-Dec       Impact factor: 4.705

8.  Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group.

Authors:  F Vincenti; R Kirkman; S Light; G Bumgardner; M Pescovitz; P Halloran; J Neylan; A Wilkinson; H Ekberg; R Gaston; L Backman; J Burdick
Journal:  N Engl J Med       Date:  1998-01-15       Impact factor: 91.245

9.  FK 506 'rescue' immunosuppression for obliterative bronchiolitis after lung transplantation.

Authors:  D J Ross; M I Lewis; M Kramer; A Vo; R M Kass
Journal:  Chest       Date:  1997-11-05       Impact factor: 9.410

10.  Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group.

Authors:  B Nashan; R Moore; P Amlot; A G Schmidt; K Abeywickrama; J P Soulillou
Journal:  Lancet       Date:  1997-10-25       Impact factor: 79.321
View more
  2 in total

1.  Interventional techniques in the management of airway complications following lung transplantation.

Authors:  Nikhil B Amesur; Philip D Orons; Aldo T Iacono
Journal:  Semin Intervent Radiol       Date:  2004-12       Impact factor: 1.513

2.  Design and physicochemical characterization of advanced spray-dried tacrolimus multifunctional particles for inhalation.

Authors:  Xiao Wu; Don Hayes; Joseph B Zwischenberger; Robert J Kuhn; Heidi M Mansour
Journal:  Drug Des Devel Ther       Date:  2013-02-04       Impact factor: 4.162
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.